Loading
A phase 2 trial of Mifamurtide and Sorafenib in Osteosarcoma, run by Anna Raciborska, now recruiting.
Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma is a phase 2 interventional study registered as NCT07787429 by Anna Raciborska, with 40 participants planned, started 2026-04-01 and due to reach its primary completion in 2033-07-31. Interventions recorded: Mifamurtide, Sorafenib. Conditions recorded: Osteosarcoma.
Linked to the drug Mifamurtide because the registry names it among its interventions and Osteosarcoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Mifamurtide, Osteosarcoma and the tag pipeline.
Shares Mifamurtide, Osteosarcoma and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.
Shares Sorafenib and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.
Shares Osteosarcoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/